News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Marwan Fakih: Privileged to present R Phase 2 study results of BOT +/- BAL in chemoresistant MSS CRC at ASCO GI25
Marwan Fakih/X
Jan 28, 2025, 17:23

Marwan Fakih: Privileged to present R Phase 2 study results of BOT +/- BAL in chemoresistant MSS CRC at ASCO GI25

Marwan Fakih, Associate Director for Clinical Sciences at City of Hope, shared a post on X:

“Today, at GI ASCO, I had the privilege of presenting the results of R Phase 2 study of BOT +/- BAL in chemoresistant MSS CRC – an area in dire need of treatment options. BOT75/BAL240 ORR 19%, DCR 55%. BAL value confirmed. Majority study responses ongoing. Durable responses matter.”

Marwan Fakih: Privileged to present R Phase 2 study results of BOT +/- BAL in chemoresistant MSS CRC at ASCO GI25

More posts featuring Marwan Fakih.

ASCO GI 25 cancer colorectal cancer Marwan Fakih MSS CRC OncoDaily Oncology
Special Coverage
Oncolibrary
Apr 25, 2025, 02:46
FDA Approves Penpulimab for Recurrent or Metastatic Non-Keratinizing Nasopharyngeal Carcinoma
Career
Apr 24, 2025, 21:39
Triparna Sen: I am thrilled and humbled to be nominated as a candidate for the IASLC Board of Directors
Blog
Apr 24, 2025, 21:05
Liz O’Riordan: 25 things I wish I had known before I got breast cancer
Blog
Apr 24, 2025, 20:53
Signing Ceremony of MoU Between Doha University for Science and Technology and Qatar Cancer Society
Blog
Apr 24, 2025, 20:40
Yan Leyfman: How AI is transforming cancer care - from improving diagnosis to reducing disparities
Insight
Apr 24, 2025, 20:28
Fernando Campos: We revealed a harsh Brazilian reality in Sarcoma Study
Insight
Apr 24, 2025, 19:38
George Vlachogiannis: Black patients were less likely to receive nephrectomy compared to non-Hispanic White patients
Blog
Apr 24, 2025, 18:30
Paolo Tarantino: Recent ADCs took a median time of 7 years from clinical introduction to approval
Blog
Apr 24, 2025, 17:56
Milestones from Philippine Cervical Cancer Elimination Operational Plan Workshop - APAC Women's Cancer Coalition
Blog
Apr 24, 2025, 17:55
Julie S. Torode: Attending my first ever AACR conference this week - long over due
Blog
Apr 24, 2025, 17:41
The Ohio State’s James Cancer Hospital and Solove Research Institute Welcomes Dr. Kimryn Rathmell as New CEO
Blog
Apr 24, 2025, 17:36
Bishal Gyawali: WHO EML working group discussion on checkpoint inhibitors for solid cancers